<DOC>
	<DOCNO>NCT01223209</DOCNO>
	<brief_summary>This study involve test medicine LTX-315 combined cancer vaccine ( GV1001 ) . This tested patient surgery curative intent malignant tumour . GV1001 peptide vaccine development treat cancer . An adjuvant , required start immune response body effect GV-1001 . LTX-315 , also peptide , development cancer treatment . In study , investigator wish find whether LTX-315 make GV1001 effective stimulating immune system .</brief_summary>
	<brief_title>A Study , Combination , Immunologic Study LTX-315 Adjunct GV1001 Patients Following Curative Surgery Carcinoma</brief_title>
	<detailed_description>This clinical study two main aim : - To measure immunological effect LTX-315 combination GV1001 - Find side effect combination two drug This open label , single centre study assess immunological effect safety LTX-315 give adjunct GV1001 . The LTX-315 dose escalate GV1001 dose fix . LTX-315 GV1001 give intradermal injection day 1 , 8 , 15 , 22 36 . Investigational treatment : LTX-315 ( 0.10 mL ) escalate concentration inject intradermally , follow , 1-2 hour later , intradermal injection 0.56 mg GV1001 ( 0.20 mL , 2.8 mg/mL ) site , one arm . DTH-test control : 0.10 mg GV1001 ( 0.10 mL ) inject intradermally contralateral arm without LTX-315 , DTH skin reactivity test control .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Curative surgery carcinoma perform least three month prior treatment start Age ≥18 year ECOG Performance status ( PS ) : 0 Life expectancy : least 3 month Laboratory requirement : White Blood Count ( WBC ) ≥ 3 x 109/L Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Haemoglobin ≥ 10.0 g/dL Total bilirubin level ≤ 1.5 ULN AST ALT ≤ 2.5 x ULN Creatinine ≥ 1.5 ULN Albumin &gt; 30 g/L No expectation anticancer therapy immunotherapy trial period , hormone therapy give adjunctive contraceptive therapy permit Must willing practice acceptable barrier method birth control prevent pregnancy The patient willing able comply protocol agree return hospital followup visit examination The patient fully inform study sign informed consent form Has receive investigational drug within 4 week prior study drug administration , schedule receive one treatment posttreatment period Has receive immunotherapy vaccinate within 12 week prior study drug administration recover adverse event due agent Has receive external radiotherapy cytotoxic chemotherapy within last 4 week prior study drug administration , recover adverse event ( &lt; Grade 1 ) due agent administer 4 week earlier Has receive imiquimod within 12 week prior study drug administration recover associated adverse event Is currently agent know effect immune system Has serious illness medical condition limit : Any uncontrolled infection infection require antibiotic Uncontrolled cardiac failure Classification III IV ( New York Heart Association ) Uncontrolled systemic gastrointestinal inflammatory condition Bone marrow dysplasia History autoimmune disease History adverse reaction vaccine Known history positive test HIV/AIDS , hepatitis B C Is pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Curative surgery</keyword>
	<keyword>Curative surgery carcinoma least three month 5 year prior treatment start</keyword>
</DOC>